Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Local Anesthetics: Clinical Application as Epidural Anesthesia

Local Anesthetics: Clinical Application as Epidural Anesthesia

Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

'The UK Maternity Crisis: Analysing the Underlying Causes to Find Solutions': The Timing of Prophylactic Caesarean Antibiotics.

BJOG : an international journal of obstetrics and gynaecology·2026

Same author

Association of novel intra-cesarean post-placental intrauterine device insertion techniques, and early ultrasound, with expulsion rates and strings visibility: A prospective exploratory study.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026

Same author

Injectable contraceptives differentially affect the hypothalamic-pituitary-gonadal axis and amenorrhea incidence†.

Biology of reproduction·2026

Same author

Diagnostic criteria for postpartum haemorrhage treatment: a cost-effectiveness study.

The Lancet. Global health·2025

Same author

When are postpartum haemorrhages diagnosed? A nested observational study within the E-MOTIVE cluster-randomised trial.

The Lancet. Global health·2025

Same author

Achieving Equitable Access to Obstetric Devices Through Innovation, Improvisation and Off-Label Use.

BJOG : an international journal of obstetrics and gynaecology·2025

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures

Published on: July 12, 2024

Tranexamic acid for preventing postpartum haemorrhage.

Natalia Novikova¹, G Justus Hofmeyr

¹Women's Health and Neonatology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, NSW, Australia, 2050.

The Cochrane Database of Systematic Reviews

|July 9, 2010

Summary

Tranexamic acid effectively reduces postpartum blood loss in women after vaginal birth and caesarean section. This antifibrinolytic agent shows promise for preventing excessive bleeding, though further research is needed.

Related Experiment Videos

Last Updated: Jun 11, 2026

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures

Published on: July 12, 2024

Area of Science:

Obstetrics and Gynecology
Pharmacology
Evidence-Based Medicine

Background:

Postpartum haemorrhage (PPH) is a significant complication of childbirth.
Existing PPH prevention methods require further improvement for safety and cost-effectiveness.
Tranexamic acid, an antifibrinolytic, warrants evaluation for PPH prevention.

Purpose of the Study:

To assess the efficacy of tranexamic acid in preventing postpartum haemorrhage (PPH).

Main Methods:

Systematic search of the Cochrane Pregnancy and Childbirth Group's Trials Register.
Inclusion of published, unpublished, and ongoing randomized controlled trials (RCTs) evaluating tranexamic acid for PPH prevention.
Independent assessment of studies by two reviewers, with data analysis using Review Manager software.

Main Results:

Two RCTs involving 453 women were included.
Tranexamic acid (0.5g or 1g IV) reduced blood loss >400ml in vaginal births and caesarean sections (RR 0.51, 95% CI 0.36 to 0.72).
Mean postpartum blood loss was significantly lower in women receiving tranexamic acid (MD -75.17 ml, 95% CI -108.23 to -42.12 ml), with no serious side effects reported.

Conclusions:

Tranexamic acid demonstrates efficacy in decreasing postpartum blood loss following vaginal birth and caesarean section.
The current evidence is based on two RCTs of unclear quality, necessitating further investigation into the regimen's efficacy and safety for PPH prevention.